UK First to Approve Eli Lilly’s Weight Loss Pill Foundayo
The UK has become the first European nation to authorize Eli Lilly’s weight management pill, Foundayo, for type 2 diabetes treatment. Despite approval, it is not yet available through the NHS. This GLP-1 tablet has gained momentum in the U.S. but trails behind Novo Nordisk’s Wegovy pill
Devdiscourse News Desk|Updated: 10-08-2026 20:50 IST | Created: 10-08-2026 20:50 IST
- Country:
- United Kingdom
Analyzing article…
The British medicines regulator has approved Eli Lilly’s Foundayo pill, marking a first in Europe for weight management and type 2 diabetes treatment
The announcement boosted shares of the Indianapolis-based pharmaceutical company by over 2% during morning trading
Although approved for use in the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) clarified that Foundayo is not currently available through the National Health Service (NHS). Eli Lilly has yet to comment on the pricing and availability strategy for the UK market. The tablet targets the GLP-1 hormone and has gained popularity in the U.S. since its approval in April, although it still lags behind Novo Nordisk’s rival Wegovy pill
ALSO READ
Pharmaceutical Titans Invest Big in U.S. Manufacturing Expansion
UK Greenlights First Ever GLP-1 Weight Loss Pill
